About
Orbsen Therapeutics is a Galway, Ireland-based biotechnology company developing cell therapies based on mesenchymal stromal cells (ORBCEL™) for indications including diabetic foot ulcers, acute respiratory distress syndrome (ARDS), diabetic kidney disease, and primary sclerosing cholangitis. The company is conducting clinical studies such as the NEPHSTROM proof-of-concept trial to advance its proprietary cell therapy pipeline.
Explore Orbsen Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.